Cepheid (CPHD) : Integrated Investment Consultants reduced its stake in Cepheid by 2.11% during the most recent quarter end. The investment management company now holds a total of 3,059 shares of Cepheid which is valued at $161,087 after selling 66 shares in Cepheid , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Cepheid makes up approximately 0.08% of Integrated Investment Consultants’s portfolio.
Other Hedge Funds, Including , Simplex Trading sold out all of its stake in CPHD during the most recent quarter. The investment firm sold 2,943 shares of CPHD which is valued $155,243. Advisory Services Network added CPHD to its portfolio by purchasing 300 company shares during the most recent quarter which is valued at $15,825.Bnp Paribas Arbitrage Sa boosted its stake in CPHD in the latest quarter, The investment management firm added 4,087 additional shares and now holds a total of 23,754 shares of Cepheid which is valued at $1,251,598. Cepheid makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio.Independent Portfolio Consultants boosted its stake in CPHD in the latest quarter, The investment management firm added 255 additional shares and now holds a total of 5,335 shares of Cepheid which is valued at $281,101. Cepheid makes up approx 0.09% of Independent Portfolio Consultants’s portfolio.
Cepheid closed down -0.06 points or -0.11% at $52.66 with 12,72,100 shares getting traded on Friday. Post opening the session at $52.74, the shares hit an intraday low of $52.655 and an intraday high of $52.85 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Cepheid reported $0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.00. The company had revenue of $146.00 million for the quarter, compared to analysts expectations of $145.92 million. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.
Many Wall Street Analysts have commented on Cepheid. Cepheid was Downgraded by Citigroup to ” Neutral” on Sep 8, 2016. Cepheid was Downgraded by Piper Jaffray to ” Neutral” on Sep 6, 2016.
Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.